229 related articles for article (PubMed ID: 37207207)
1. Elevated
Cheng Q; Wang W; Liu J; Lv Z; Ji W; Yu J; Zhang W; Yang Y
Front Immunol; 2023; 14():1173848. PubMed ID: 37207207
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
Chen J; Gao G; Zhang Y; Dai P; Huang Y
BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
[TBL] [Abstract][Full Text] [Related]
3. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
4. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Li L; Wang X; Ding Y; Hui N; Su B; Yang M
Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879
[TBL] [Abstract][Full Text] [Related]
5. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
6. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
7. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
8. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
9. PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest.
Wang X; Yang J; Luo L; Li X; Zhang Y
Aging (Albany NY); 2023 May; 15(10):4122-4143. PubMed ID: 37211383
[TBL] [Abstract][Full Text] [Related]
10. TMEM147 Correlates with Immune Infiltration and Serve as a Potential Prognostic Biomarker in Hepatocellular Carcinoma.
Cheng S; Li J; Xu M; Bao Q; Wu J; Sun P; Han B
Anal Cell Pathol (Amst); 2023; 2023():4413049. PubMed ID: 37305689
[TBL] [Abstract][Full Text] [Related]
11.
Li D; Huang S; Luo C; Xu Y; Fu S; Liu K; Wu J
Curr Oncol; 2023 Feb; 30(3):2653-2672. PubMed ID: 36975415
[TBL] [Abstract][Full Text] [Related]
12. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
13. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
14. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
15. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
16. Exploration of Key Genes Combining with Immune Infiltration Level and Tumor Mutational Burden in Hepatocellular Carcinoma.
Chen J; Zhang L; Lu CH; Xu CZ
Comb Chem High Throughput Screen; 2024 Jan; ():. PubMed ID: 38213141
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and immune roles of UROC1 in human cancers: from mechanism exploration of NAFLD and HCC to pan-cancer analysis.
Wang QY; Liu YJ; Hu Y; Xiao H; Xia LL; Wu YG
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):622-644. PubMed ID: 38305606
[TBL] [Abstract][Full Text] [Related]
18. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
19. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.
Du M; Qu Y; Qin L; Zheng J; Sun W
J Cell Mol Med; 2024 Apr; 28(7):e18168. PubMed ID: 38494848
[TBL] [Abstract][Full Text] [Related]
20. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]